Clinical trials: Diabetes, Type 1
Diabetes Mellitus, Type 1
United Kingdom User Evaluation, MiniMed Paradigm® X54 System
The user evaluation is to assess user acceptance and the quality of training materials for the MiniMed Paradigm® X54 System (X54 System) in preparation for commercial distribution of the new system.
- Trial name
- X54User (NCT01267175)
- Testing
- X54 insulin pump with low suspend feature
- Where
- 6 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Diabetes Mellitus, Type 1
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
This study is conducted in Europe and Asia. The purpose of the study (Diabetes Pregnancy Registry) is to evaluate the safety of treatment with insulin detemir in pregnant women with diabetes mellitus.
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01892319
- Testing
- insulin detemir, other injectable antidiabetic treatment regimens
- Where
- 93 sites in Croatia, Finland and 14 more
- Volunteers
- 2,446 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients
The aim of this extension study is to assess the safety and efficacy of Mylan's insulin glargine and Lantus® in T1DM patients.
- Trial name
- NCT02666430
- Testing
- Mylan's insulin glargine, Lantus®
- Where
- 81 sites in United States, Canada and 6 more
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
Type 1 Diabetes Mellitus
Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes
This clinical study will evaluate the safety of an innovative approach expected to be disease-modifying by stopping the auto-immune-mediated destruction of islet β-cells in the pancreas.
- Trial name
- NCT03272269
- Testing
- IMCY-0098
- Where
- 17 sites in Belgium, Denmark and 5 more
- Volunteers
- 41 people
- Sponsor
- Imcyse SA
Diabetes Mellitus, Type 2
A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.
To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.
- Trial name
- NCT05411965
- Testing
- BR3003(T), BR3003B(R1), BR3003C(R2)
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 1 Diabetes Mellitus
Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting
Feasibility study assessing the ability of an insulin pump-controlling algorithm to minimize hypoglycemia and hyperglycemia in patients with type 1 diabetes in a clinical research setting.
- Trial name
- NCT01638299
- Testing
- Hypo-Hyper Minimizer (HHM) System
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Type 1 Diabetes, Eating Disorders
Eating Disorders in Type 1 Insulin-dependent Diabetes Patients
The purpose of this study is to determine the prevalence of eating disorders in type 1 insulin-dependent diabetes patients
- Trial name
- Diaboulimia (NCT04506216)
- Testing
- cohort
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Icadom
Type 1 Diabetes (T1D)
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems
TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes.
- Trial name
- Hybrid CATT1 (NCT07616206)
- Testing
- Cadisegliatin 800 mg QD
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- vTv Therapeutics
Diabetes Mellitus
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
To assess the safety and effectiveness of a next-generation automated insulin delivery algorithm in participants aged 16+ years with type 1 or type 2 diabetes.
- Trial name
- Evolution (NCT06181721)
- Testing
- Omnipod 5 Automated Glucose Control System
- Where
- New Zealand
- Volunteers
- 20 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus, Non-Insulin-Dependent
Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione
The purpose of this study is to assess the efficacy and safety of Amaryl when added to Metformin and Thiazolidinedione (TZD) in non-insulin dependent diabetes mellitus (NIDDM) patients.
- Trial name
- NCT00044447
- Testing
- Glimepiride
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia
Primary Objective: To assess the pharmacodynamic response (PD) of a single subcutaneous (SC) dose of SAR438544 versus recombinant glucagon in type 1 diabetes mellitus (T1DM) patients under induced hypoglycemia.
- Trial name
- NCT02635243
- Testing
- SAR438544, r-glucagon, insulin
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
This study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014 (Lyumjev) on blood sugar levels during exercise…
- Trial name
- NCT05262387
- Testing
- Lyumjev with 50% basal rate reduction, Humalog with 50% basal rate reduction, Humalog with 100% basal rate reduction
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Human Insulin NPH and Insulin Aspart in Type 1 Diabetes
This trial is conducted in South America. This aim of this trial is to evaluate the comparative prandial blood glucose lowering profile in subjects with type 1 diabetes.
- Trial name
- NCT00597233
- Testing
- insulin aspart, soluble human insulin, insulin NPH
- Where
- Argentina
- Volunteers
- 91 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus
The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar.
- Trial name
- NCT03341299
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus
PF-04603629 is being investigated for the treatment of Type 2 diabetes mellitus (T2DM). Specifically, PF-04603629 is a protein that is a combination of exendin-4 (a glucagon-like peptide-1 (GLP-1) mimetic currently marketed as…
- Trial name
- NCT00637338
- Testing
- PF-04603629
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pfizer
Type 1 Diabetes
Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy
Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group".
- Trial name
- STAR3 (NCT00417989)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 30 sites in United States, Canada
- Volunteers
- 485 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
The study involves a single injection of LY2963016 and a single injection of Lantus, on 2 separate occasions in participants with type I diabetes.
- Trial name
- NCT01600950
- Testing
- LY2963016, Lantus
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects
PF 04603629 is a long acting exendin proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and glucose lowering capabilities following a…
- Trial name
- NCT00638313
- Testing
- PF-04603629
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Pfizer
Type 1 Diabetes Mellitis
Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients
The goal of this clinical trial is to demonstrate the non-inferior immunogenicity of GP40321 compared to Apidra® SoloStar® at a concentration of 100 U/mL in type 1 diabetes mellitus patients.
- Trial name
- NCT07070752
- Testing
- GP40321, Apidra® SoloStar®, RinGlar®
- Where
- 17 sites in Russia
- Volunteers
- 224 people
- Sponsor
- Geropharm
Diabetes Mellitus, Diabetes Mellitus, Adult-Onset
Classification of Adult-onset Diabetes in Five Subgroups in Pakistani Population
This study aims to classify adult-onset diabetes patients into distinct data-driven clusters, such as severe insulin-deficient, severe insulin-resistant, mild obesity-related, and mild age-related diabetes, based on clinical and…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Adult-Onset, Diabetes Mellitus Type 1 and 2
- Trial name
- NCT06706609
- Volunteers
- 394 people
- Sponsor
- Getz Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.